184 related articles for article (PubMed ID: 37052701)
21. CAR NK92 Cells Targeting BCMA Can Effectively Kill Multiple Myeloma Cells Both In Vitro and In Vivo.
Park E; Mun HJ; Seo E; Hwang S; Lee JH; Song S; Sung H; Kim HY; Kwon MJ
Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38275419
[TBL] [Abstract][Full Text] [Related]
22. Antigen-primed CD8+ T cells can mediate resistance, preventing allogeneic marrow engraftment in the simultaneous absence of perforin-, CD95L-, TNFR1-, and TRAIL-dependent killing.
Komatsu M; Mammolenti M; Jones M; Jurecic R; Sayers TJ; Levy RB
Blood; 2003 May; 101(10):3991-9. PubMed ID: 12521999
[TBL] [Abstract][Full Text] [Related]
23. Natural Killer Cell Group 7 Sequence in Cytotoxic Cells Optimizes Exocytosis of Lytic Granules Essential for the Perforin-Dependent, but Not Fas Ligand-Dependent, Cytolytic Pathway.
Morikawa Y; Murakami M; Kondo H; Nemoto N; Iwabuchi K; Eshima K
Immunohorizons; 2021 Apr; 5(4):234-245. PubMed ID: 33911019
[TBL] [Abstract][Full Text] [Related]
24. [Killing effect of Robo1 targeted Chimeric Antigen Receptor modified NK92 cells against glioma and neuroblastoma cells].
Qu Y; Bi JZ
Zhonghua Yi Xue Za Zhi; 2018 Mar; 98(11):860-866. PubMed ID: 29609271
[No Abstract] [Full Text] [Related]
25. Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome.
Cifaldi L; Prencipe G; Caiello I; Bracaglia C; Locatelli F; De Benedetti F; Strippoli R
Arthritis Rheumatol; 2015 Nov; 67(11):3037-46. PubMed ID: 26251193
[TBL] [Abstract][Full Text] [Related]
26. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
[TBL] [Abstract][Full Text] [Related]
27. CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma.
Schomer NT; Jiang ZK; Lloyd MI; Klingemann H; Boissel L
Cytotherapy; 2022 Aug; 24(8):827-834. PubMed ID: 35400595
[TBL] [Abstract][Full Text] [Related]
28. Escaping Death: How Cancer Cells and Infected Cells Resist Cell-Mediated Cytotoxicity.
Tuomela K; Ambrose AR; Davis DM
Front Immunol; 2022; 13():867098. PubMed ID: 35401556
[TBL] [Abstract][Full Text] [Related]
29. Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL.
Ureña-Bailén G; Dobrowolski JM; Hou Y; Dirlam A; Roig-Merino A; Schleicher S; Atar D; Seitz C; Feucht J; Antony JS; Mohammadian Gol T; Handgretinger R; Mezger M
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361619
[TBL] [Abstract][Full Text] [Related]
30. Transferrin epitope-CD19-CAR-T cells effectively kill lymphoma cells
Valentine M; Li L; Zhou H; Xu S; Sun J; Liu C; Harto H; Berahovich R; Golubovskaya V; Wu L
Front Biosci (Landmark Ed); 2020 Jan; 25(2):270-282. PubMed ID: 31585889
[TBL] [Abstract][Full Text] [Related]
31. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
32. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
[TBL] [Abstract][Full Text] [Related]
33. Optimized cytotoxicity assay for co-suspended effector and target cells.
Cui L; Yin F; Cheng J; Liu H; Zheng M; Liu D; Wu Z; Qian Q
J Immunol Methods; 2021 Oct; 497():113100. PubMed ID: 34270976
[TBL] [Abstract][Full Text] [Related]
34. A chimeric switch-receptor PD1-DAP10-41BB augments NK92-cell activation and killing for human lung Cancer H1299 Cell.
Zhi L; Yin M; Su X; Zhang Z; Lu H; Li M; Guo C; Niu Z; Zhang X; Zhu W
Biochem Biophys Res Commun; 2022 Apr; 600():94-100. PubMed ID: 35217362
[TBL] [Abstract][Full Text] [Related]
35. Antigen-induced cell death of T effector cells in vitro proceeds via the Fas pathway, requires endogenous interferon-gamma and is independent of perforin and granzymes.
Sobek V; Balkow S; Körner H; Simon MM
Eur J Immunol; 2002 Sep; 32(9):2490-9. PubMed ID: 12207333
[TBL] [Abstract][Full Text] [Related]
36. Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy.
Yang M; Wang L; Ni M; Neuber B; Wang S; Gong W; Sauer T; Schubert ML; Hückelhoven-Krauss A; Xia R; Ge J; Kleist C; Eckstein V; Sellner L; Müller-Tidow C; Dreger P; Schmitt M; Schmitt A
Front Immunol; 2021; 12():670088. PubMed ID: 34122428
[TBL] [Abstract][Full Text] [Related]
37. Distinguishing perforin-mediated lysis and granzyme-dependent apoptosis.
Rudd-Schmidt JA; Trapani JA; Voskoboinik I
Methods Enzymol; 2019; 629():291-306. PubMed ID: 31727246
[TBL] [Abstract][Full Text] [Related]
38. Effects of total flavonoids of sea buckthorn ( Hippophae rhamnoides L.) on cytotoxicity of NK92-MI cells.
Hou D; Wang D; Ma X; Chen W; Guo S; Guan H
Int J Immunopathol Pharmacol; 2017 Dec; 30(4):353-361. PubMed ID: 28994628
[TBL] [Abstract][Full Text] [Related]
39. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
[TBL] [Abstract][Full Text] [Related]
40. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.
Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
